From Pulse 2.0 · Amit Chowdhry · · 1m
Pfizer Q3 Revenue Boosts 2026 Guidance
Pfizer's $16.6B Q3 revenue and 32% growth in newer medicines lift 2026 financial outlook.
In brief
Pfizer's $16.6B Q3 revenue and 32% growth in newer medicines lift 2026 financial outlook. Pfizer raised full-year 2026 revenue guidance to $62-64 billion after strong Q3 performance with newer medicines growing 32% operationally. Originally reported by Pulse 2.0.
Pfizer Q3 Revenue
Pfizer reported third-quarter 2026 revenue of $16.583 billion, slightly below prior-year revenue of $16.654 billion.
Operational Revenue Growth
Excluding COVID-19 products, Pfizer's newer medicines delivered 7% operational revenue growth.
Product Performance
Pfizer's launched and acquired products generated 32% operational revenue growth.
Key Product Gains
Eliquis revenue increased $513 million (25%), Padcev grew $255 million (55%), and Vyndaqel rose $193 million (12%).
Product Challenges
Paxlovid revenue dropped $771 million (63%) as Comirnaty sales fell $339 million (29%).
Financial Guidance
Pfizer raised full-year 2026 revenue guidance to $62-64 billion from $60.5-62.5 billion.
CEO Statement
Dr. Albert Bourla highlighted strong commercial momentum and pipeline progress for long-term shareholder value.
“Pfizer had another strong quarter with commercial momentum and disciplined execution while advancing our strategy for creating long-term shareholder value. Our obesity program continued to advance and recent milestones in oncology, immunology and vaccines further demonstrate the potential of our pipeline. With a robust slate of expected catalysts ahead, i believe we’re well positioned to deliver meaningful new medicines for patients and lasting value in the years ahead.”
The big picture
Pfizer raised full-year 2026 revenue guidance to $62-64 billion after strong Q3 performance with newer medicines growing 32% operationally.
